

MARKED UP VERSION OF AMENDED CLAIMS

12. (Amended) The compound according to [any one of claims 8 to 11] claim 8 wherein X^2 is a bond, $-CH_2-$, $-S-$, $-SO_2-$, $-CH_2-O-$, $-O-CH_2-$, $-CH_2-S-$ or $-S-CH_2-$, the prodrug, the pharmaceutically acceptable salt, the hydrate thereof.

13. (Amended) The compound according to [any one of claims 8 to 12] claim 8 wherein R^1 is $-CH_2-CH=CH-CH_2-CH_2-CH_2-COOH$, m is 0, and p is 0, the prodrug, the pharmaceutically acceptable salt, the hydrate thereof.

14. (Amended) A pharmaceutical composition which comprises a compound according to [any one of claims 8 to 13] claim 8.

15. (Amended) A pharmaceutical composition having a dual antagonistic activity against PGD_2/TXA_2 receptors which comprises a compound according to [any one of claims 8 to 13] claim 8.

16. (Amended) The pharmaceutical composition comprising a compound according to claim 14 [or 15], which is used for asthma.

17. (Amended) The pharmaceutical composition comprising a compound according to claim 14 [or 15], which is used for nasal blockage.

18. (Amended) Use of the compound according to [any one of claims 8 to 13] claim 8 for manufacturing a pharmaceutical composition for asthma or nasal blockage.

19. (Amended) A method for treating asthma or nasal blockage which comprises administering the compound according to [any one of claims 8 to 13] claim 8.